Core Viewpoint - ProVerum has successfully completed a $80 million Series B funding round to advance its ProVee system, a novel treatment option for benign prostatic hyperplasia (BPH) patients, positioned between medication and surgery [2][3]. Company and Team - ProVerum was founded by two researchers from Trinity College Dublin, Conor Harkin and Ríona Ní Ghriallais, who identified a gap in treatment options for BPH patients [4][5]. - The company has a small team of approximately 30 people, focusing on integrating material engineering, urology, and industry transformation to expedite product development [5]. Product and Technology - ProVee is a "reversible" prostate stent designed to alleviate symptoms of BPH, which significantly impacts patients' quality of life [6][10]. - The stent addresses a significant treatment gap between medication and surgery, providing a less invasive option for patients [6][24]. - ProVee's design avoids common issues associated with traditional metal stents, such as encrustation and irritation, and is adaptable to various anatomical structures [15][19]. Clinical Trials and Market Significance - The ProVIDE study, a multi-center, randomized, double-blind trial, included 221 BPH patients and demonstrated significant improvements in symptoms and safety [19][21]. - Results showed that patients receiving ProVee experienced a notable reduction in International Prostate Symptom Score (IPSS) and improved urinary flow rates without serious adverse events [21][24]. - ProVee aims to fill the "middle layer" treatment space, reducing the burden on patients and healthcare systems by offering a simple outpatient procedure [23][24]. Industry Observation - The global BPH patient population exceeds 94 million, with many not receiving effective treatment, highlighting a substantial market opportunity for ProVee [24][25]. - ProVee's unique features, such as reversibility and outpatient applicability, position it favorably against existing treatments like UroLift and Rezūm [25][27]. Conclusion - ProVerum's ProVee stent represents a potential breakthrough in BPH treatment, aiming to redefine patient experiences and fill a critical gap in the market between medication and surgical options [25][27].